SCHEMBL7087725

SCHEMBL7087725

CC1Oc2ccc(C(Cc3ccc(F)cc3)NC(=O)OC(C)(C)C)cc2NC1=S

nearest known ligand 0.41

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CTSS P25774 2/20 0.41
CTSK P43235 2/20 0.41
ALDH1A1 P00352 7/20 0.37
HTT P42858 5/20 0.37
NPSR1 Q6W5P4 5/20 0.37
HPGD P15428 4/20 0.37
HSD17B10 Q99714 3/20 0.37
TP53 P04637 2/20 0.37
JAK2 O60674 2/20 0.37
MAPK1 P28482 1/20 0.37
ATM Q13315 1/20 0.37
LMNA P02545 4/20 0.37
TSHR P16473 4/20 0.37
KMT2A Q03164 3/20 0.37
MEN1 O00255 2/20 0.37
SCN9A Q15858 3/20 0.35
PKM P14618 3/20 0.35
MAPT P10636 1/20 0.35
AGTR1 P30556 1/20 0.35
RAB9A P51151 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL7095640 0.92 ALDH1A1 (0.37) ALDH1A1HTTNPSR1HPGDHSD17B10
SCHEMBL7092472 0.91 HSD17B10 (0.37) ALDH1A1HTTNPSR1HPGDHSD17B10
SCHEMBL7704943 0.91 ALDH1A1 (0.43) CTSSCTSKALDH1A1HTTNPSR1
SCHEMBL7090483 0.91 CTSS (0.45) CTSSCTSKALDH1A1HTTNPSR1
SCHEMBL7094044 0.90 SMN1; SMN2 (0.40) ALDH1A1HTTNPSR1HPGDHSD17B10
SCHEMBL7708144 0.90 PARP1 (0.42) CTSSCTSKALDH1A1HTTNPSR1
SCHEMBL7092669 0.90 CTSS (0.34) CTSSCTSKALDH1A1HTTNPSR1
SCHEMBL7093832 0.89 PTPRB (0.37) ALDH1A1HTTNPSR1HPGDHSD17B10
SCHEMBL7710783 0.88 PPARG (0.39) ALDH1A1HTTNPSR1HPGDHSD17B10
SCHEMBL7095139 0.88 CA2 (0.41) ALDH1A1HTTNPSR1HPGDHSD17B10

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1015437-B1 BENZOXAZINE AND BENZOTHIAZINE DERIVATIVES AND THEIR USE IN PHARMACEUTICALS SCHERING AG (DE) 2003-12-03 EP disclosed
US-6365736-B1 TREATMENT OF NERVOUS SYSTEM DISORDERS, CARDIOVASCULAR DISORDERS AND FOR ACTIVITY AS NO-SYNTHASES (NOS) INHIBITORS. SCHERING AKTIENGESELLSCHAFT (DE) 2002-04-02 US disclosed